Leerink Partnrs Analysts Reduce Earnings Estimates for ARWR

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Research analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of ($0.92) per share for the year, down from their prior estimate of $0.10. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97).

A number of other equities analysts have also recently issued reports on ARWR. Royal Bank of Canada restated an "outperform" rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Piper Sandler reduced their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating on the stock in a report on Wednesday, November 27th. Citigroup lowered their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating for the company in a research report on Wednesday, November 27th. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Finally, Chardan Capital reissued a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $41.44.

Remove Ads

Arrowhead Pharmaceuticals Trading Up 4.7 %

Shares of NASDAQ ARWR traded up $0.70 during mid-day trading on Thursday, hitting $15.50. The stock had a trading volume of 1,193,058 shares, compared to its average volume of 1,262,977. The business has a 50 day moving average price of $18.51 and a two-hundred day moving average price of $19.81. Arrowhead Pharmaceuticals has a 1 year low of $14.23 and a 1 year high of $30.41. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The firm has a market cap of $2.13 billion, a P/E ratio of -3.00 and a beta of 0.92.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC raised its holdings in Arrowhead Pharmaceuticals by 25.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock worth $208,889,000 after buying an additional 2,222,223 shares during the last quarter. State Street Corp raised its holdings in Arrowhead Pharmaceuticals by 8.8% in the 3rd quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company's stock worth $123,083,000 after acquiring an additional 516,569 shares during the last quarter. Slate Path Capital LP lifted its position in Arrowhead Pharmaceuticals by 7.1% in the 4th quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock valued at $98,362,000 after acquiring an additional 347,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in Arrowhead Pharmaceuticals by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company's stock valued at $57,426,000 after purchasing an additional 26,171 shares during the last quarter. Finally, Norges Bank purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $38,622,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Adeoye Y. Olukotun sold 2,850 shares of the business's stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. Following the sale, the director now directly owns 36,740 shares of the company's stock, valued at $734,800. The trade was a 7.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Christopher Richard Anzalone sold 51,425 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the transaction, the chief executive officer now directly owns 4,062,377 shares of the company's stock, valued at approximately $61,220,021.39. This trade represents a 1.25 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 289,167 shares of company stock worth $5,106,735. Corporate insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.